Item 8.01 Other Events On July 24, 2024, MacroGenics, Inc. (the “ Company”) and Incyte Corporation (together with the Company, the “ Parties”) entered into a Fourth Amendment (the “ Amendment”) to the Parties’ existing Global Collaboration and License Agreement, dated as of October 24, 2017, as amended on March 15, 2018, April 7, 2022 and July 14, 2022 (collectively, the “ Agreement”), pursuant to which the Parties agreed that certain development milestones under the Agreement were deemed to be achieved, resulting in a $100 million payment to the Company. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which will be filed in redacted form as an exhibit to the Company’s Quarterly Report on Form 10-Q for the period ending September 30, 2024. On July 30, 2024, the Company issued a press release announcing the Amendment (the “ Press Release”). The full text of the Press Release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Description of Exhibit 99.1 Press Release dated July 30, 2024 ────────────────────────────────────────────────────────────────────────────────────────────── 104 Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 30, 2024 MACROGENICS, INC. ───────────────────────────────────────────────────────────────────────────────────────────── By: /s/ Jeffrey Peters